Valeant Pharmaceuticals International (NYSE:VRX) has tumbled 8.7% during the past week and has dropped 19.77% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.6%. Valeant Pharmaceuticals International (NYSE:VRX) has underperformed the index by 20.5% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Valeant Pharmaceuticals International (NYSE:VRX): The stock opened at $22.42 on Friday but the bulls could not build on the opening and the stock topped out at $22.63 for the day. The stock traded down to $21.96 during the day, due to lack of any buying support eventually closed down at $22.04 with a loss of -1.69% for the day. The stock had closed at $22.42 on the previous day. The total traded volume was 22,955,510 shares.
The company shares have dropped -90.34% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $263.81 and the one year low was seen on Jun 17, 2016. The 50-Day Moving Average price is $27.82 and the 200 Day Moving Average price is recorded at $61.01.
On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Valeant Pharmaceuticals International, Inc., Papa Joseph C had purchased shares worth of $4,944,960 in a transaction dated on June 10, 2016. A total of 202,000 shares were purchased at a price of $24.48 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. Jefferies maintains their rating on the shares of Valeant Pharmaceuticals International (NYSE:VRX). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $40 per share from $53 per share. The rating by the firm was issued on June 8, 2016. Currently the company Insiders own 8.62% of Valeant Pharmaceuticals International shares according to the proxy statements. Institutional Investors own 78.75% of Valeant Pharmaceuticals International shares.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.